LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses.
Ta HM, Roy D, Zhang K, Alban T, Juric I, Dong J, Parthasarathy PB, Patnaik S, Delaney E, Gilmour C, Zakeri A, Shukla N, Rupani A, Phoon YP, Liu C, Avril S, Gastman B, Chan T, Wang LL.
Ta HM, et al. Among authors: rupani a.
Sci Immunol. 2024 May 17;9(95):eadi7418. doi: 10.1126/sciimmunol.adi7418. Epub 2024 May 17.
Sci Immunol. 2024.
PMID: 38758807
Free PMC article.